<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00196755</url>
  </required_header>
  <id_info>
    <org_study_id>REN00304</org_study_id>
    <nct_id>NCT00196755</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis</brief_title>
  <official_title>An Open Label, Randomized, Parallel Design Study to Investigate the Efficacy and Safety of Sevelamer Hydrochloride (Renagel®) Compared With Calcium Acetate in Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that sevelamer hydrochloride is non-inferior to
      calcium acetate for the treatment of hyperphosphataemia in patients receiving peritoneal
      dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the effects of sevelamer dosed three times per day (TID) and calcium acetate dosed TID on serum phosphorus.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum calcium- phosphorus (CaxPO4) product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipids - total and LDL cholesterol, non- HDL cholesterol, HDL, triglycerides</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma biomarkers: random blood glucose, glycosylated haemoglobin, bone specific alkaline phosphatase, uric acid and c-reactive protein</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Peritoneal Dialysis</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Sevelamer Hydrochloride (Renagel®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium acetate (PhosLo® )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer Hydrochloride (Renagel®)</intervention_name>
    <description>Sevelamer hydrochloride three times per day with each meal</description>
    <arm_group_label>Sevelamer Hydrochloride (Renagel®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium acetate (PhosLo® )</intervention_name>
    <description>Calcium acetate three times per day with each meal</description>
    <arm_group_label>Calcium acetate (PhosLo® )</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to sign an informed consent form.

          -  Men or women aged 18 years of age or older.

          -  A diagnosis of Chronic Kidney Disease (CKD) and receiving peritoneal dialysis
             (Continuous cyclical peritoneal dialysis (CAPD), Automated peritoneal dialysis (APD)
             or Continuous cyclical peritoneal dialysis (CCPD) for 8 weeks or longer.

          -  In the opinion of the investigator, expected to receive peritoneal dialysis for the
             duration of the study.

          -  Will have a serum phosphorus level &gt;1.76 mmol/L(5.50 mg/dL) after 2 weeks washout from
             their usual phosphate binder.

          -  Will have serum calcium measurement adjusted for albumin within the range (2.10-2.60
             mmol/L (8.40-10.40 mg/dL) following 2 weeks washout from their usual phosphate binder.

          -  Willing to maintain the prescribed sevelamer or calcium acetate for the duration of
             the study.

          -  Considered compliant with phosphate binders and dialysis.

          -  On a stable doses of medication to treat hyperparathyroidism (Vitamin D or its
             analogues or calcimimetic agents) for the month prior to screening.

          -  Willing to discontinue use of antacids containing calcium, aluminium or magnesium at
             screening visit for the duration of the study (unless taken as an evening calcium
             supplement as prescribed by the investigator per protocol).

          -  Willing to avoid intentional changes in diet such as fasting or dieting.

          -  If female and of childbearing potential (pre-menopausal and not surgically sterile),
             willing to use an effective contraceptive method throughout study, which includes
             barrier methods, hormones, or Intrauterine devices (IUDs).

          -  Have a level of understanding and willingness to cooperate with all visits and
             procedures as described by the study personnel.

        Exclusion Criteria:

          -  Patients with a history of peritonitis in the last 30 days or &gt; 2 episodes in the last
             12 months

          -  Patient with active dysphagia, swallowing disorder, bowel obstruction, or severe
             gastrointestinal motility disorder.

          -  Patients who in the opinion of the investigator have poorly controlled diabetes
             mellitus, poorly controlled hypertension, active vasculitis, Human Immunodeficiency
             Virus (HIV) infection, or any clinically significant, unstable medical condition.

          -  Patients with any evidence of active malignancy except for basal cell carcinoma of the
             skin. A history of malignancy is not exclusion.

          -  Current use of an antiarrhythmic medication such as quinidine, procainamide,
             tocainide, or amiodarone for the control of arrhythmias.

          -  Current use of a seizure medication such as phenytoin, phenobarbital, valproate, or
             carbamazepine for the control of a seizure disorder.

          -  Active ethanol or drug abuse, excluding tobacco use.

          -  If female, are pregnant, planning on becoming pregnant in the next 6 months or
             breast-feeding.

          -  Patients with a known hypersensitivity to sevelamer or any constituents of either
             study drug.

          -  Patients who have participated in a study of an investigational drug/device during the
             30 days preceding the start of the screening period.

          -  Patients who have any other condition, which in the opinion of the investigator will
             prohibit the patient's participation in the study.

          -  Patient is unable to comply with the requirements of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fredericia Sygehus</name>
      <address>
        <city>Fredericia</city>
        <zip>DN-7000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DN-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Århus N</city>
        <zip>DN-8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Clémenceau</name>
      <address>
        <city>Caen</city>
        <zip>FR-14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale civico e benfratelli</name>
      <address>
        <city>Palermo</city>
        <zip>IT-90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <zip>IT-36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>NL-1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>ES-28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>ES-28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital ,Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Wycombe Hospital</name>
      <address>
        <city>Buckinghamshire</city>
        <zip>HP11 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wales College of Medicine</name>
      <address>
        <city>Cardiff</city>
        <zip>CF 14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital The Royal London</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton Keynes General Hospital</name>
      <address>
        <city>Milton Keynes</city>
        <zip>MK6 5LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Churchill Hospital, Oxford Radcliffe Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2005</study_first_submitted>
  <study_first_submitted_qc>September 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>Genzyme Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Sevelamer</mesh_term>
    <mesh_term>Calcium acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

